This HTML5 document contains 33 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n23http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00088/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n22http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB00088/identifier/uniprotkb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00088/identifier/genbank/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00088/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00088/identifier/wikipedia/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n9http://www.drugs.com/cdi/
n17http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00088/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00088/identifier/drugbank/
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00088
rdf:type
n3:Drug
n3:description
Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues
n3:generalReferences
# Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S: Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009 Feb;11(2):92-100. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19265748
n3:group
approved
n3:halfLife
3.6-10.4 min
n3:indication
For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
n3:manufacturer
n4:271B442C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00088 n22:DB00088
dcterms:title
Alglucerase
adms:identifier
n6:P04062 n7:D09675 n10:58468-1060-1 n13:DB00088 n14:M16328 n15:Alglucerase n18:PA164748093
n3:mechanismOfAction
Alglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.
n3:packager
n4:271B4429-363D-11E5-9242-09173F13E4C5 n4:271B442A-363D-11E5-9242-09173F13E4C5 n4:271B442B-363D-11E5-9242-09173F13E4C5
n3:volumeOfDistribution
* 49.4 to 282.1 mL/kg
foaf:page
n9:alglucerase.html n23:ceredase.htm
n3:Molecular-Formula
n17:271B4431-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n17:271B4430-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:A16AB01
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
37228-64-1
n3:category
n3:containedIn
n21:271B442D-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n17:271B442E-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n17:271B442F-363D-11E5-9242-09173F13E4C5